Yes exactly NVAX is a good stock as is CVAC--
I'm thinking of getting back into CVAC-
I'm thinking of getting back into CVAC-
GBA's "2021 Stock Phantasma"
- Thread starter stonedinvestor
- Start date
CureVac
Up a stunning 84% since its IPO in August, German biopharma CureVac (NASDAQ:CVAC) could arguably become one of the top-performing coronavirus stocks this year. Most of the spotlight shines on its potential coronavirus mRNA vaccine, CVnCoV.
In phase 1 clinical studies, patients who received CureVac's experimental vaccine developed the same ratio of neutralizing and binding antibodies against the SARS-CoV-2 as those who were infected with the virus and subsequently recovered.
That sounds iffy to me- ))))))
There were only moderate side effects such as fatigue, headaches, fever, muscle aches, and joint pain. The experimental vaccine is also stable at standard refrigeration temperatures.
Given the reliable efficacy data and the clinical success of prior mRNA coronavirus vaccines, it is highly likely that CureVac can advance its experimental vaccine to a regulatory clearance as well. The company expects to release interim clinical data updates for its phase 1, 2, and 3 portions of CVnCoV's investigation during this quarter. If the results are promising, CureVac projects it can clear its experimental vaccine past regulatory approval as early as the second quarter of this year.
Before the final results are out, multiple governments and private organizations alike are already vouching for CVnCoV. For starters, it already has 225 million doses of pre-orders from the E.U. for the vaccine candidate. There is also an option to supply the supranational organization with 180 million further doses.
- Similar to NVAX in that they have orders) ) )
At a price tag of 10 euros per dose, this means CureVac potentially has more than 2.25 billion euros in revenue that could arrive by the year's end. That is quite impressive for a company with a market cap of $18 billion. What's more, CureVac IPO'd just last year and only has a rabies vaccine candidate, as well as two potential oncological treatments aside from CVnCoV, all of which are in early clinical testing.
It is currently collaborating with German multinational pharma company Bayer (OTC:BAYR.Y) to scale its manufacturing capacity. The company is setting a manufacturing target of 300 million doses this year and double that amount in 2022.
That's not all: The company has more than $1 billion in cash on its balance sheet compared to just $85 million in debt. The company has received various grants from the German government, as well as funding from the Coalition for Epidemic Preparedness Innovations (CEPI).
Compared to a net loss of $36.8 million in third quarter 2020, it has more than enough net assets on hand to keep up its research and development efforts without selling more stock to raise cash.
Up a stunning 84% since its IPO in August, German biopharma CureVac (NASDAQ:CVAC) could arguably become one of the top-performing coronavirus stocks this year. Most of the spotlight shines on its potential coronavirus mRNA vaccine, CVnCoV.
In phase 1 clinical studies, patients who received CureVac's experimental vaccine developed the same ratio of neutralizing and binding antibodies against the SARS-CoV-2 as those who were infected with the virus and subsequently recovered.
That sounds iffy to me- ))))))
There were only moderate side effects such as fatigue, headaches, fever, muscle aches, and joint pain. The experimental vaccine is also stable at standard refrigeration temperatures.
Given the reliable efficacy data and the clinical success of prior mRNA coronavirus vaccines, it is highly likely that CureVac can advance its experimental vaccine to a regulatory clearance as well. The company expects to release interim clinical data updates for its phase 1, 2, and 3 portions of CVnCoV's investigation during this quarter. If the results are promising, CureVac projects it can clear its experimental vaccine past regulatory approval as early as the second quarter of this year.
Before the final results are out, multiple governments and private organizations alike are already vouching for CVnCoV. For starters, it already has 225 million doses of pre-orders from the E.U. for the vaccine candidate. There is also an option to supply the supranational organization with 180 million further doses.
- Similar to NVAX in that they have orders) ) )
At a price tag of 10 euros per dose, this means CureVac potentially has more than 2.25 billion euros in revenue that could arrive by the year's end. That is quite impressive for a company with a market cap of $18 billion. What's more, CureVac IPO'd just last year and only has a rabies vaccine candidate, as well as two potential oncological treatments aside from CVnCoV, all of which are in early clinical testing.
It is currently collaborating with German multinational pharma company Bayer (OTC:BAYR.Y) to scale its manufacturing capacity. The company is setting a manufacturing target of 300 million doses this year and double that amount in 2022.
That's not all: The company has more than $1 billion in cash on its balance sheet compared to just $85 million in debt. The company has received various grants from the German government, as well as funding from the Coalition for Epidemic Preparedness Innovations (CEPI).
Compared to a net loss of $36.8 million in third quarter 2020, it has more than enough net assets on hand to keep up its research and development efforts without selling more stock to raise cash.
ROCHESTER, N.Y., Jan. 26, 2021 /PRNewswire/ -- Vuzix® Corporation (NASDAQ: VUZI), ("Vuzix" or, the "Company"), a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, today announced the Company has recently received a new follow-on commercial order for M400 Smart Glasses from Dutch medical services company 1Minuut Innovation. The latest order from 1Minuut Innovation is for immediate delivery to elderly care organizations to meet urgent COVID-19 remote healthcare needs in the Netherlands and will push the number of M400 Smart Glasses in the field deployed with 1Minuut's Genzõ software suite to over 500 units.
OPKO-
Bullishpattern detected
Double Moving Average Crossover
Bullishpattern detected
Double Moving Average Crossover
It's a shame Robin Hood just crashed. I feel like they are so close to discovering Opko.-
I would like to be in one of these names that goes to the moon for no reason. Checkout FIZZ
that's that crappy Lacroix--
I would like to be in one of these names that goes to the moon for no reason. Checkout FIZZ
that's that crappy Lacroix--
Every time CVAC drops in price I want to buy it, but I'm trying to keep to just one vaccine play. you feel a bit like a sitting duck waiting for the results to come in. i've held some NVAX shares long, but did some swing trading on it just to build profit as a buffer in case the whole thing craps out.
Wow-
Skillz Inc. (SKLZ) went $2 lower than this!!!!
NYSE - Nasdaq Real Time Price. Currency in USD
$28.00-1.73 (-5.80%)
As of 10:19AM EST.
Skillz Inc. (SKLZ) went $2 lower than this!!!!
NYSE - Nasdaq Real Time Price. Currency in USD
$28.00-1.73 (-5.80%)
As of 10:19AM EST.
Foley Trasimene Acquisition Corp. II (BFT)- To Be Paysafe I believe... (from memory)
NYSE - Nasdaq Real Time Price. Currency in USD
$15.94-0.74 (-4.44%)
This unit came from Blackstone. So it is apt to be very well run. That being said there are probably not that many cost cutting synergies left --
NYSE - Nasdaq Real Time Price. Currency in USD
$15.94-0.74 (-4.44%)
This unit came from Blackstone. So it is apt to be very well run. That being said there are probably not that many cost cutting synergies left --
On Dec. 7, it was announced that BFT had signed a definitive agreement and plan of merger with Paysafe Group, an integrated payments platform. Upon closing of the transaction, the newly combined company will operate as Paysafe and plans to list on the New York Stock Exchange under the symbol PSFE.
The transaction reflects an implied pro-forma enterprise value for Paysafe of approximately $9 billion. Paysafe operates a payments platform with a two-sided consumer and merchant network, whose core purpose is to enable businesses and consumers to connect and transact through payment processing, digital wallet, and online cash solutions.
Existing Paysafe equity holders, including Blackstone (BX) , CVC, and management, will remain the largest investors in the company. The transaction is expected to close in the first half of 2021.
The great appeal here is the payment platform sector. There are currently two main competitors -- Square (SQ) and PayPal (PYPL) . As the Paysafe story becomes more widely understood, it should attract additional interest.
Look at this way. The holding co was $9-$10 before the deal. Rapid rise to $13. Are you that far away? For what you have gained?
The transaction reflects an implied pro-forma enterprise value for Paysafe of approximately $9 billion. Paysafe operates a payments platform with a two-sided consumer and merchant network, whose core purpose is to enable businesses and consumers to connect and transact through payment processing, digital wallet, and online cash solutions.
Existing Paysafe equity holders, including Blackstone (BX) , CVC, and management, will remain the largest investors in the company. The transaction is expected to close in the first half of 2021.
The great appeal here is the payment platform sector. There are currently two main competitors -- Square (SQ) and PayPal (PYPL) . As the Paysafe story becomes more widely understood, it should attract additional interest.
Look at this way. The holding co was $9-$10 before the deal. Rapid rise to $13. Are you that far away? For what you have gained?
VUZI turns positive is RH back online?